Dry Eye Disease (DED) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Dry Eye Disease (DED) Market Outlook
Thelansis’s “Dry Eye Disease (DED)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Dry Eye Disease (DED) treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Dry Eye
Disease (DED) Overview
Dry eye
disease (DED), also referred to as keratoconjunctivitis sicca, is a prevalent
and persistent condition affecting the ocular surface. It is characterized by
an inability to produce an adequate quantity or quality of tears to moisturize
the eyes. Several common risk factors contribute to this syndrome, including
aging, being female, exposure to low-humidity environments, using certain
systemic medications, and autoimmune disorders. DED is categorized into two
main types: “dry eye with reduced tear production,” referred to as aqueous
deficient, and “dry eye with increased tear film evaporation,” known as the
hyper-evaporative type. Among those affected, about 10% suffer from aqueous
deficient DED, while more than 80% experience the hyper-evaporative type, often
related to meibomian gland dysfunction (MGD) or a combination of both. The
consequences of DED can be substantial, significantly impacting one’s vision
and overall quality of life. The associated symptoms often interfere with
everyday tasks such as writing, reading, or working on video display monitors.
Consequently, the primary objectives of DED treatment are to alleviate ocular
discomfort, enhance the patient’s quality of life, and restore the ocular
surface and tear film to their natural states, preventing any further harm to
the eye tissue and cornea. Various pharmacological therapies are available as
part of the treatment arsenal.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment